The 4 Stages of Kidney Decline — and Why the First 3 Are Still Addressable Without Dialysis

By Dr. Andrea Galvin, Kidney Specialist

Chronic kidney disease has four stages. The first three are addressable without dialysis. Most American doctors will not tell you that — because they are only trained to manage stage four.

I have been a kidney specialist for 22 years, the first 20 in Zurich. When I moved to the United States, I saw the same thing over and over: patients in their 50s and 60s with declining eGFR, swollen ankles, three nighttime bathroom trips, and one sentence in common — "my doctor has been monitoring it for years." Monitoring is not the same as addressing it. Here is what is actually happening at each stage — and where you still have a window.

First — what's actually driving the decline.

Your kidneys filter through microscopic units called glomeruli — a mesh finer than a human hair. Three mechanisms destroy that mesh, simultaneously:

1. The TLR4/NF-kB inflammatory cascade — the primary pathway fraying the filtration threads.
2. Mitochondrial oxidative stress — in the cells filtering 200 litres of blood a day.
3. Fibrosis — scar tissue permanently replacing filtration capacity.

Your ACE inhibitor manages the pressure on those structures. That is the full extent of what it does. It does not suppress the cascade, protect the mitochondria, or activate the anti-fibrotic pathways. That is why the number keeps falling no matter how well your blood pressure is controlled — and why the stages progress.

Stage 1

The silent stage — where almost nobody acts.

The eGFR drops slightly. Maybe mild ankle puffiness by evening. Nothing alarming. Your doctor says reduce protein and stay hydrated, and it seems manageable. But underneath, the three mechanisms have already started — the cascade is early, the fibrosis minimal. This is the fastest stage to address, because the filtration structures are still highly responsive. Most people who act here see measurable UACR improvement within six weeks.

Stage 2

What happens underneath while the numbers "look managed."

The eGFR begins dropping faster. The UACR — protein leaking through the damaged net — starts climbing. Ankle puffiness becomes noticeable. Nighttime bathroom trips multiply. Lower-back heaviness becomes a constant companion. The medication dose gets adjusted, the numbers stabilise briefly, then decline again — and the adjustment window narrows every cycle. The fibrosis is building. Addressing the root cause takes longer here, but is still very achievable — most people see measurable UACR reduction in six to eight weeks as the cascade calms.

Stage 3

The critical window — when the body starts compensating visibly.

The remaining nephrons work harder to cover for the ones fibrosis destroyed. They filter more aggressively, accumulate oxidative damage faster, and the cascade runs harder against fewer threads. The fatigue arrives — not ordinary tiredness, but the specific exhaustion of kidneys working twice as hard with half the capacity. Brain fog. Energy gone by afternoon. Social plans cancelled. Every outing calculated around bathroom access. This is the critical window. The filtration structures that remain are still responsive — the cascade can still be suppressed, the oxidative damage reduced, the anti-fibrotic pathways activated. Every month you wait makes stage four more likely.

Stage 4

The dialysis conversation.

Your doctor begins mentioning dialysis planning in the future tense. Transplant-list consideration. The scar tissue is extensive, the filtration capacity critically reduced, and all three mechanisms are running at full intensity against what little architecture remains. Even here, the most important thing is to slow the mechanisms from destroying what filtration capacity is left. This is not a worst-case scenario I'm inventing — it is what I watch happen, step by step, in patients who were told for years to keep monitoring and adjust the medication.

Where the stages matter for YOU — right now.

What the research points to — and why the form matters.

A randomised controlled trial of 98 Stage 3–4 CKD patients showed eGFR improving from 31.8 to 45.6 in three months, creatinine down 18.3%, and urinary protein down 36.7% — backed by a meta-analysis of 15 studies and 1,310 patients, the Cochrane review, and a 2025 Frontiers in Pharmacology paper on the anti-fibrotic pathways. The compound is Cordyceps militaris fruiting body extract, whose active — cordycepin — suppresses the cascade, protects the mitochondria, and activates the anti-fibrotic pathways. All three, at once.

But here is what almost sends people away: most products on the shelf use mycelium grown on grain, not the actual fruiting body the research used — a fraction of the cordycepin, if any. People take it for six weeks, feel nothing, and conclude "Cordyceps doesn't work." They were taking grain starch with a mountain photo on the label. The form has to be right, or it does nothing.

The formula I recommend to my own patients is Adoria:

One scoop into your morning coffee. I have no financial relationship with this company — I recommend it because the mechanism is sound, the research is published, and the formulation matches what the trials actually used.

And you can measure it. Ask your doctor for a baseline UACR (the urinary albumin-to-creatinine ratio — it moves faster than eGFR). Retest at six weeks. Let the number tell you whether the three mechanisms are finally being addressed. Not a feeling. A number.

Your kidneys don't have to wait for the system to catch up.
The first three stages are still a window. Use it.